Lenglet, Aurelie
Fabresse, Nicolas
Taupin, Méline
Gomila, Cathy
Liabeuf, Sophie
Kamel, Said
Alvarez, Jean Claude
Drueke, Tilman B.
Massy, Ziad A.
Article History
First Online: 6 May 2019
Compliance with Ethical Standards
:
: This study was funded by an interregional Grant (PHRC IR08: 2008-004673-17).
: Ziad A. Massy reports grants for CKD REIN and other research projects from Amgen, Baxter, Fresenius Medical Care, GlaxoSmithKline, Merck Sharp and Dohme-Chibret, Sanofi-Genzyme, Lilly, Otsuka, and the French Government, as well as fees and grants to charities from Astellas, Baxter, Daichii, Medice, and Sanofi-Genzyme. These sources of funding are not necessarily related to the content of the present manuscript. Tilman B. Drueke reports fees for advisor/consultant services from Amgen, F. Hoffman-La Roche, FMC, Glaxo-Smith-Kline, KfH-Stiftung Präventivmedizin, Sanofi-Genzyme, and Vifor and speaker fees from Akebia, Amgen, Astellas, Chugai, Kyowa Hakko Kirin, and Sanofi-Genzyme. Aurelie Lenglet, Nicolas Fabresse, Méline Taupin, Cathy Gomila, Sophie Liabeuf, Said Kamel, and Jean Claude Alvarez have no conflicts of interest that are directly relevant to the content of this article.
: The protocol was approved by a local investigational review board (CPP Nord Ouest II, Amiens, France; reference 2008-004673-17) and implemented in accordance with the ethical principles of the Declaration of Helsinki (ClinicalTrials.gov registration number NCT01011699).